University of the Pacific Thomas J. Long School of Pharmacy
Driven by a commitment to achieve excellence since 1955, the Thomas J. Long School of Pharmacy trains pharmacists to excel as problem-solvers, innovators and leaders in their careers. By choosing University of the Pacific's three-year accelerated doctor of pharmacy (PharmD) program, students become part of our legacy of excellence and leadership.
The skill set and clinical experience gained from our PharmD program open new doors to the many settings where pharmacists play a key role -- from hospitals to pharmaceutical research and development. Through each component of our PharmD curriculum, students learn how to become a pharmacist who leads with excellence.
From the first semester, students develop patient-care skills that are integrated throughout the PharmD curriculum, exposing them to the administrative, pharmaceutical, social, behavioral and clinical science aspects of the field of pharmacy. This combination allows students to develop a solid foundation of practical training by gaining patient care experience across a wide variety of settings.
The School is home to a robust interprofessional education (IPE) curriculum that supports PharmD students. Through IPE, students engage in case-based learning, simulations, peer teaching, telehealth simulations and innovative gaming techniques such as escape room scenarios. They also apply teamwork skills and learned concepts in interprofessional practice experiences during their Introductory Pharmacy Practice Experiences (IPPE) and Advanced Pharmacy Practice Experiences (APPE).
The Thomas J. Long School of Pharmacy is committed to the success of our students. To ensure that each of our PharmD graduates are prepared for their careers, we offer a first-of-its- kind, immersive three-week residential California Practice Standards and Jurisprudence Examination (CPJE) and North American Pharmacist Licensure Exam (NAPLEX) preparatory program.
This comprehensive program is designed to build on students' strengths through targeted practice sessions and engaging reviews and complements other available resources. In their third year, all students also complete 'Rx Prep' to begin early preparation for licensure exams.
At Pacific, students have the opportunity to work alongside faculty members on cutting-edge research. Current projects focus on novel drug delivery systems, innovative drug design and forward- thinking approaches to patient care. Our faculty have also earned international recognition for their research on diabetes and consumer products.
While pursuing their PharmD, students can customize their education through two distinct and dynamic pathways: clinical pharmacology and entrepreneurship.
The clinical pharmacology pathway prepares students with a comprehensive understanding of clinical drug development and equips them to contribute to evidence-based decision-making in drug therapy and development.
The entrepreneurship pathway provides future scientists with a strong foundation in pharmaceutical business operations and the entrepreneurial skills needed to launch and lead ventures focused on novel drug products and medical devices.
The School's dual-degree programs combine the clinical training of the PharmD with immersive research through the Pharmaceutical and Chemical Sciences Program, preparing PharmD/MS and PharmD/PhD graduates for high- demand roles in industry and academia.
Learn more and apply today at Pacific.edu/PharmD
University of the Pacific
Thomas J. Long School of Pharmacy
Berit Gundersen, PharmD
1851
1955
530
Doctor of Pharmacy (PharmD)
Pathways:Clinical pharmacologyEntrepreneurship
Dual-degrees:PharmD/MSPharmD/PhD
3 years
In 2024, following a rigorous review, the Accreditation Council for Pharmacy Education (ACPE) granted Pacific's doctor of pharmacy program an eight-year reaccreditation.
2025-26: $235,784
Final application deadline: June 6, 2025
Tony Williams, Director of RecruitmentOffice of Pharmacy Admission209.932.3600pharmdadmission@pacific.edu Pacific.edu/PharmD
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Vaxart Announces Adjournment of Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ('Vaxart' or the 'Company') announced today that its 2025 annual meeting of stockholders (the 'Annual Meeting') has been adjourned to Friday, June 13, 2025 at 8:30 a.m. Pacific Time with respect to all proposals described in Vaxart's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the 'SEC') on April 10, 2025 (the 'Proxy Statement'). 'In recent days, we have engaged in constructive conversations with some of our larger stockholders to address their questions and concerns regarding the reverse stock split proposal,' said Steven Lo, Chief Executive Officer of Vaxart. 'I am pleased to report that following these discussions, many have indicated their intention to vote in favor of Proposal No. 2. This shift underscores the increasing understanding of the necessity of this proposal to ensure our continued Nasdaq listing as we focus on our exciting upcoming milestones.' The reconvened Annual Meeting will be held in a virtual-only format, which can be accessed by visiting and entering the 16‐digit control number included in your Notice of Internet Availability of Proxy Materials, on your proxy card or in the instructions that accompanied your proxy materials. During the adjournment, Vaxart continues to solicit votes from its stockholders with respect to all proposals set forth in the Proxy Statement. Proxies previously submitted with respect to the Annual Meeting will be voted on all applicable proposals at the adjourned Annual Meeting unless properly revoked in accordance with the procedures described in the Proxy Statement, and stockholders who have previously submitted a proxy or otherwise voted need not take any action. Both leading independent proxy advisory firms, Institutional Shareholder Services ('ISS') and Glass Lewis, recommend that stockholders support Proposal No. 2. A message from Dr. Sean Tucker, Founder and Chief Scientific Officer, and a fact sheet that addresses several misconceptions about the proposed reverse stock split can be found on Vaxart's investor relations website at Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 12, 2025. The Company also reminds those who have previously voted against Proposal No. 2 that they can change their vote in favor of the proposal. If you have any questions or need assistance with voting, please contact Vaxart's proxy solicitation firm: Campaign Management, LLCToll-Free: 1-855-264-1527Email: info@ About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are subject to the 'safe harbor' created by those sections, concerning our business, operations, and financial performance and condition as well as the annual meeting of stockholders, our plans, objectives, and expectations for business operations, funding, and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as 'anticipate,' 'assume,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'should,' 'will,' 'would,' and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this press release may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under 'Item 1A - Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and any risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this press release. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this press release. Participants in the SolicitationThe Company and its directors, executive officers, and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the business to be conducted at the annual meeting of stockholders. Investors and security holders may obtain more detailed information regarding the names, affiliations, and interests of the Company's directors and executive officers in the definitive proxy statement filed in connection with the annual meeting of stockholders as well as the Company's other filings with the U.S. Securities and Exchange Commission (the 'SEC'), all of which may be obtained free of charge at the website maintained by the SEC at Contact Vaxart Media and Investor RelationsMatt SteinbergFINN PartnersIR@ 871-8481 This press release was published by a CLEAR® Verified in to access your portfolio
Yahoo
2 days ago
- Yahoo
Legal Storm Intensifies Around BJ Penn, New Developments Emerge: Report
Legal Storm Intensifies Around BJ Penn, New Developments Emerge: Report originally appeared on Athlon Sports. BJ Penn's legacy as a UFC Hall of Famer has entered a new phase, as recent reports shed light on developments outside the cage. Known for his accomplishments in both the lightweight and welterweight divisions, Penn now finds himself under increased public scrutiny as legal proceedings continue. Over the past several years, various incidents have drawn attention, and recent reports have added more context to his situation. Advertisement In a recent report published by Hawaii Tribune-Herald, new details surfaced regarding Penn's absence from a scheduled court hearing connected to a domestic abuse case. A widely shared post online stated, 'In a surprising turn of events, UFC Hall of Famer BJ Penn skips his scheduled court appearance in a domestic abuse case following multiple arrests over Memorial Day weekend. The fallout continues to unfold as his legal troubles raise eyebrows.' This latest update has brought renewed focus to Penn's legal history. More recently, Penn has drawn headlines after publishing a series of alarming social media posts claiming that close family members—including his mother and brothers—had been replaced by imposters. His mother, Lorraine Shin, responded by filing a restraining order, citing emotional distress and extreme psychological abuse. Court filings also referenced Capgras delusional syndrome, a rare disorder marked by the belief that loved ones have been replaced. Around the same time, Penn was arrested twice over Memorial Day weekend on family abuse charges, following incidents involving his mother and a violation of a prior warning citation. These details were first reported by Kauai Now News, a local Hawaii-based news outlet covering legal and community issues. Each of these developments has contributed to ongoing public interest and raised concerns about his well-being. BJ Penn As of now, Penn has not publicly addressed the most recent court-related development. The situation remains ongoing, with further updates expected as proceedings move forward. Advertisement Related: UFC Makes Announcement About Nashville Card Related: 'He's Overrated' – Jon Jones Fires at Former UFC Interim Champion This story was originally reported by Athlon Sports on May 30, 2025, where it first appeared.
Yahoo
2 days ago
- Yahoo
Major disaster from three years ago could impact Australia's winters for years
A major natural disaster that occurred two years ago could be impacting Australia's climate this winter, and may continue to do so for a number of years. Scientists say they are 'surprised' by the results in their study, which showed the effects may be felt around the world for up to a decade. On January 15, 2022, an underwater volcano off the Pacific nation of Tonga exploded, releasing 1,000 times more energy than the Hiroshima bomb. It was one of the most powerful volcanic eruptions in recent history, and sent up to 150 million tonnes of water vapour into the stratosphere. A study into the long-term impacts of that water vapour injection found it may temporarily alter local climates, including cooler winters in Australia, warmer winters and spring in North America, drier summers over northern Eurasia, and more rain over China's east coast. Lead author and senior lecturer of the Climate Change Research Centre at UNSW, Martin Jucker, told Yahoo News it was "really unusual" for volcanoes to leave such a long-lasting impact. "Volcanoes are generally known to impact the global climate, but that's usually a cooling due to all the smoke and for a few years. It's usually more like two to three years, not eight years." He also said the research was complex, as a multitude of things can impact the weather and worsen or placate their findings. 'One very important thing about our study is that we look into the future, and there's no way to know how the global mean temperature or sea surface temperature, El Nino, El Nina, and all of these things, how they would look in the future. So we didn't include any of those effects. I only included the volcano and nothing else,' Jucker said. In Australia, the study found anomalies in surface temperature that could see winters get up to 1°C cooler. Those in Western Australia may also see slightly lower temperatures in summer and autumn. Australia's surface temperature anomalies were described in the study as the 'most persistent, with significant cooling from year 1 to 8'. The research also picked up slightly more rain than usual in WA, and wet anomalies over northern Australia. Interestingly, the anomalies peak at years three and four after the eruption, which would be this year and next year. The three-year lag is because of the composition of the stratosphere, Jucker said. 'There are no weather systems, there's no clouds, no rain, or anything, and everything moves much more slowly. This water vapour was put into the stratosphere very locally, just above the volcano. So it needed time for this water to distribute itself across the entire globe and that takes a few years," he said. The changes can be difficult to perceive, Jucker said, and may not even be noticeable until looked at as an average over the next four years or so. 'I still hope we do [see the changes] because I just find it exciting. I'm waiting to see if we can confirm it from a scientific point of view. 'We find this effect only if we average over a long time. So four years, from now to 2029, we average, and then we see this effect. Even after year three, we don't even see these effects if we just look down one individual year, for instance.' While the study found weather anomalies around the world, the cooling in Australia and warming over North America don't have an overall impact on global temperature as they 'cancel out'. "Now, what we did find is these regional impacts which would be starting about now, so three years after. And so they globally, they sum up to zero, but locally, there's a cooling," Jucker said. "There's a cooling that we expect in winter over Australia over this time period, but there's a warming in North America in their winter, for instance. So all of these things cancel out, but regionally they're there." He added that, like all scientific studies, it's important to remember that his findings are not definitive. "So even when I say, we expect colder winters over Australia, it's really the probability of it being colder is higher. But it could be warmer, and that's fine. That would still be within our results. It's just that the probability of it being colder is higher," he said. One prediction that has so far proven correct in Jucker's study is that the volcano's eruption would contribute to a hole in the ozone layer. The large hole appeared from August to December in 2023, which is what his simulations picked up almost two years in advance. Do you have a story tip? Email: newsroomau@ You can also follow us on Facebook, Instagram, TikTok, Twitter and YouTube.
